United States · Series B startup

Who invested in FogPharma

One round we have observed, with the 8 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Funding summaryUpdated 26 Oct 2026

$66Mraised across 1 round since 2018, from 1 source

Latest round
Series B, $66MMay 2018
Investors
8
See who backed them

The rounds

  1. May 2018

Founders and team

From FogPharma's own website: 3 on the team.

  • Sheryl JacobsSenior Vice President, Development Operations
  • Kristen StantsChief People Officer
  • Thomas KotarakosChief Financial Officer

AdvisersEdward Fitzgerald

Everyone who backed them

DeerfieldVC firm1round
Horizons VenturesVC firm1round
Boyu CapitalPrivate equity1round
WuXi AppTecGrowth equity1round
Leerink PartnersGrowth equity1round
Blue Pool CapitalPrivate equity1round
Nan Fung GroupInvestment firm1round
6 Dimensions Capital/ GVno record of our own yet1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about FogPharma

Who invested in FogPharma?

FogPharma's investors include Deerfield, Horizons Ventures, Boyu Capital, WuXi AppTec and Leerink Partners, and 3 more on record.

How much has FogPharma raised?

FogPharma has raised $66M across 1 round since 2018.

When did FogPharma last raise?

FogPharma's most recent round was a Series B of $66M in May 2018.

What was FogPharma's biggest round?

Its most recent round, $66M in May 2018, is also its largest on record.

Who backed FogPharma first?

FogPharma's first round on record, in May 2018, was backed by Deerfield, Horizons Ventures and Boyu Capital and 5 others.

What stage is FogPharma at?

FogPharma's latest named round is a Series B, in May 2018.

Where is FogPharma based?

FogPharma is based in the United States.

Companies like FogPharma

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.